EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease

Ioanna Alefanti, Christos Koros iD, Viktoria Tsami, Athina Maria Simitsi, Chrisoula Kartanou, Nikolaos Papagiannakis, Maria Bozi, Roubina Antonelou, Matina Maniati, Ann-Kathrin Hauser, Stefanos Varvaressos, Anastasios Bonakis and 9 more

European Journal of Neurology · 2025

DOI: 10.1111/ene.16562 ↗

At a glance

Journal article in European Journal of Neurology, 2025. Written by Ioanna Alefanti and 20 co-authors. Institution: 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece. Major MEDLINE topics: alpha-Synuclein, Parkinson Disease, Genetic Predisposition to Disease. Cited 2 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0). Funded by: Hellenic General Secretariat for Research and Innovation (GSRI).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The p.A53T variant in the SNCA gene was considered, until recently, to be the only SNCA variant causing familial Parkinson's disease (PD) in the Greek population. We identified a novel heterozygous p.A30G (c.89 C>G) SNCA pathogenic variant in five affected individuals of three Greek families, leading to autosomal dominant PD. This study aims to further explore the presence and phenotypic expression of this variant in the Greek PD population.

Methods

Restriction fragment length polymorphism (RFLPs) was used for genotyping of 664 Greek PD cases. Detailed clinical information was obtained for the carriers and p.A30G‐positive samples underwent haplotype analysis.

Results

We identified 10 additional p.A30G‐positive PD patients (1.5%), of whom 4 were sporadic cases (0.9%). They manifested typical Parkinsonian motor dysfunction, with a mean age of onset of 51.7 years (range: 33–62) and a broad spectrum of non‐motor symptoms. The absence of affected first degree relatives in four out of ten index cases, and the presence of a phenocopy in an additional family, suggest that the p.A30G variant manifests reduced penetrance. The common haplotype among the p.A30G carriers confirmed a founder effect. Furthermore, two asymptomatic carriers were identified, with possible premotor manifestations.

Conclusions

These findings underscore that the p.A30G SNCA pathogenic variant represents an important, albeit rare, cause of genetic PD in the Greek population. This is the first time in which a genetic synucleinopathy, with a variant in the SNCA gene, is clearly linked to an appreciable frequency of sporadic PD in a particular population.

Subjects

MeSH terms (MEDLINE)

alpha-SynucleinParkinson DiseaseGenetic Predisposition to DiseaseHumansGreeceMaleMiddle AgedFemaleAdultPedigreeHaplotypes

Author keywords

SNCAGreek populationParkinson's diseasep.A30G

Substances

alpha-SynucleinSNCA protein, human

Authors and institutions

  • 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Neurogenetics Unit, 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Laboratory of Neurodegenerative Diseases, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
  • 2nd Department of Neurology, Attikon Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen and German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Department of Medical Genetics, National and Kapodistrian University of Athens, Athens, Greece.

ORCID profiles: Christos Koros

Funding

  • Hellenic General Secretariat for Research and Innovation (GSRI)

Cite

APA

Alefanti, I., Koros, C., Tsami, V., Simitsi, A. M., Kartanou, C., Papagiannakis, N., Bozi, M., Antonelou, R., Maniati, M., Hauser, A. K., Varvaressos, S., Bonakis, A., Lourentzos, K., Makrythanasis, P., Papageorgiou, S. G., Proukakis, C., Potagas, C., Gasser, T., Koutsis, G., …, & Stefanis, L. (2025). The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease. European Journal of Neurology. https://doi.org/10.1111/ene.16562

Vancouver

Alefanti I, Koros C, Tsami V, Simitsi AM, Kartanou C, Papagiannakis N, et al. The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease. European Journal of Neurology. 2025. doi:10.1111/ene.16562

BibTeX
@article{Alefanti2025,
  author = {Alefanti, Ioanna and Koros, Christos and Tsami, Viktoria and Simitsi, Athina Maria and Kartanou, Chrisoula and Papagiannakis, Nikolaos and Bozi, Maria and Antonelou, Roubina and Maniati, Matina and Hauser, Ann-Kathrin and Varvaressos, Stefanos and Bonakis, Anastasios and Lourentzos, Konstantinos and Makrythanasis, Periklis and Papageorgiou, Sokratis G and Proukakis, Christos and Potagas, Constantinos and Gasser, Thomas and Koutsis, Georgios and Karadima, Georgia and Stefanis, Leonidas},
  title = {The novel p. A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.16562}
}
Start for free →